GLP2T - tirzepatide

Rows are ordered by price per mg: listed price divided by stated peptide content, excluding shipping and codes, so every vial competes on the same axis. Each row carries its own $/mg figure, so the size of the gap between vendors is visible, not just the order. Sprays follow the vials, unranked.

The best-documented testing flag goes to the vendor publishing batch-level, third-party certificates. The shipping flag goes to the fastest published delivery from a domestic warehouse. Data is re-checked on a schedule and each row carries its verification date.

Dual GIP/GLP-1 receptor agonist — next-generation weight loss and metabolic-health peptide.

A 39-residue synthetic peptide reported in the primary literature to engage both the GIP and GLP-1 receptors in in-vitro cAMP assays. For laboratory characterisation only.

GLP2-T (Tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist. 2026 meta-analyses confirm superiority over semaglutide: -22.1% weight loss vs -17.1% at 12 months, with 95.2% achieving ≥10% loss. SURPASS trials show HbA1c reductions of 1.8-2.4%. Ongoing cardiovascular outcomes study (NCT07096063) compares long-term MACE endpoints vs semaglutide.

In-vitro cAMP assays report full agonism at the GIP receptor. The molecule is described as GIP-biased relative to native peptides.

In-vitro engagement of the GLP-1 receptor is reduced relative to native GLP-1; described in the primary literature as a partial agonist profile.

In-vitro / preclinical characterisation only — no clinical or therapeutic claim is expressed or implied. Research use only.

GLP2-T is a synthetic 39-amino-acid dual incretin receptor agonist. GLP2-T (Tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist. 2026 meta-analyses confirm superiority over semaglutide: -22.1% weight loss vs -17.1% at 12 months, with 95.2% achieving ≥10% loss. SURPASS trials show HbA1c reductions of 1.8-2.4%. Ongoing cardiovascular outcomes study (NCT07096063) compares long-term MACE endpoints vs semaglutide. It has a molecular formula C225H348N48O68, mass 4813.45 Da. Common synonyms in the literature include Tirzepatide, tirzepatide, and LY3298176.

Investigation of GLP2-T to date is clinical-investigational, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing GLP2-T spans SURPASS clinical trial program (Type 2 Diabetes): Seven Phase 3 trials comparing glp2-t (5, 10, 15 mg weekly) to placebo, glp1-s, insulin degludec, and insulin glargine. SURPASS-2 showed superior HbA1c reductions vs. glp1-s 1 mg (-2.0% to -2.3% vs. -1.9%). SURPASS-CVOT demonstrated non-inferiority for MACE with 10% risk reduction vs. dulaglutide, SURMOUNT clinical trial program (Obesity): SURMOUNT-1 (n=2,539) in non-diabetic adults showed 15 mg dose achieved 22.5% mean weight loss at 72 weeks vs. 2.4% placebo. SURMOUNT-2 in T2D patients showed 14.7% weight loss. SURMOUNT-3 and -4 evaluated weight maintenance and different populations, and Mechanism studies: Research demonstrates glp2-t enhances glucose-dependent insulin secretion more than selective GLP-1 agonists, likely through GIP-mediated potentiation. Studies show preferential fat mass reduction (fat:lean ratio ~8:1) compared to caloric restriction alone. Proposed mechanisms in the literature include GIPR full agonism: mimics native GIP, enhances post-meal insulin secretion, promotes lipid clearance and fat oxidation and GLP-1R biased partial agonism: favors cAMP over β-arrestin signaling, weaker receptor internalization vs native GLP-1. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for GLP2-T outside laboratory research.

For the full mechanistic profile, published references, and constraint notes on GLP2-T, see the GLP2-T research page. All references cited on that page are peer-reviewed primary literature.

Binding and functional-assay data for GLP2-T, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.

Structural and in-vitro receptor-binding attributes of published incretin research compounds. Reference chemistry only — no comparative-effectiveness claim expressed or implied.